MARKET

NEO

NEO

Neogenomics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

49.40
-0.54
-1.08%
Opening 09:30 09/24 EDT
OPEN
49.53
PREV CLOSE
49.94
HIGH
49.55
LOW
49.32
VOLUME
6.03K
TURNOVER
--
52 WEEK HIGH
61.57
52 WEEK LOW
34.18
MARKET CAP
6.07B
P/E (TTM)
89.85
1D
5D
1M
3M
1Y
5Y
NeoGenomics' Liquid Biopsy Subsidiary Inivata And Collaborators To Present Data That Further Validate The Application Of Its RaDaR(TM) MRD And InVisionFirst(R)-Lung Assays At The ESMO Congress 2021
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that its liquid biopsy focused subsidiary Inivata Limited
Benzinga · 09/09 11:07
NeoGenomics' Liquid Biopsy Subsidiary Inivata and Collaborators to Present Data that Further Validate the Application of its RaDaR(TM) MRD and InVisionFirst(R)-Lung Assays at the ESMO Congress 2021
FT MYERS, FL / ACCESSWIRE / September 9, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that its liquid biopsy focused subsidiary Inivata ...
ACCESSWIRE · 09/09 11:00
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
Zacks.com · 09/09 10:20
Artisan Partners on NeoGenomics (NEO): “We Remain Excited About the Company”
Artisan Partners, a high value-added investment management firm, published its ‘Artisan Small Cap Fund’ second quarter 2021 investor letter – a copy of which can be downloaded here. A return of 4.36% was recorded by its Investor Class: ARTSX, 4.40% by its ...
Insider Monkey · 09/06 17:14
NeoGenomics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
MYERS, FL / ACCESSWIRE / September 1, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Mark Mallon, Chief Executive Officer, Kathryn Mc...
ACCESSWIRE · 09/01 20:05
--Benchmark Capital Adjusts NeoGenomics' Price Target to $50 From $46, Maintains Buy Rating
MT Newswires · 08/26 07:40
Soleus Capital Management, L.P. Buys BioAtla Inc, NeuroPace Inc, C4 Therapeutics Inc, Sells ...
GuruFocus News · 08/23 21:38
Is NeoGenomics (NASDAQ:NEO) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Simply Wall St. · 08/23 12:56
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NEO. Analyze the recent business situations of Neogenomics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NEO stock price target is 56.80 with a high estimate of 65.00 and a low estimate of 50.00.
EPS
Institutional Holdings
Institutions: 427
Institutional Holdings: 119.95M
% Owned: 97.67%
Shares Outstanding: 122.82M
TypeInstitutionsShares
Increased
115
9.63M
New
40
1.16M
Decreased
118
4.77M
Sold Out
47
705.82K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Healthcare Facilities & Services
+0.16%
Healthcare Providers & Services
+0.16%
Key Executives
Chairman/Executive Director
Douglas VanOort
Chief Executive Officer/Director
Mark Mallon
Chief Financial Officer
Kathryn McKenzie
Corporate Executive
William Bonello
Corporate Executive
George Cardoza
Corporate Executive
Clive Morris
Corporate Executive
Gina Wallar
Chief Accounting Officer/Controller
Cynthia Dieter
Chief Marketing Officer
Marcus Silva
Chief Compliance Officer
Stephanie Bywater
General Counsel/Secretary
Denise Pedulla
Other/IR Contact Officer
Douglas Brown
Other
Jennifer Balliet
Lead Director/Independent Director
Lynn Tetrault
Independent Director
Bruce Crowther
Independent Director
Alison Hannah
Independent Director
Kevin Johnson
Independent Director
Stephen Kanovsky
Independent Director
Michael Kelly
Independent Director
Rachel Stahler
No Data
  • All
  • Financials
  • Insiders
More
About NEO
NeoGenomics, Inc. is an operator of a network of cancer-focused testing laboratories. The Company’s customers include Clinical and Pharma. Its Clinical customers include community-based pathology practices, oncology groups, hospitals and academic centers. Its Pharma customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials. The Company offers testing services, which include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry (IHC) and digital imaging, molecular testing and morphologic analysis. The Company' Pharma Services segment provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. It helps its customers develop a biomarker hypothesis by recommending an optimal platform for molecular screening and backing its discovery tools with the informatics to capture meaningful data.

Webull offers kinds of NeoGenomics, Inc. stock information, including NASDAQ:NEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NEO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NEO stock methods without spending real money on the virtual paper trading platform.